A Mycobacterium leprae lambda gt11 clone designated T5 has previously been selected with sera from tuberculoid leprosy patients. Sequence analysis of this clone revealed the presence of two overlapping open reading frames (ORFs) present on the two cDNA strands. The first ORF codes for the serologically recognized antigen, which was fused with the lacZ gene in the lambda gt11 clone. The second ORF, present on the complementary strand, displays strong sequence homology with the aspartyl-tRNA synthetase genes of Escherichia coli and Thermus thermophilus. Here we show that the purified T5-derived product, overexpressed in E. coli, is recognized by T cells of the majority of the leprosy patients tested, including lepromatous leprosy patients who do not respond to whole M. leprae bacilli.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC173672 | PMC |
http://dx.doi.org/10.1128/iai.63.12.4682-4685.1995 | DOI Listing |
BMJ Case Rep
January 2025
Dermatology, Venereology and Leprosy, AIIMS Rishikesh, Rishikesh, Uttarakhand, India
Paediatric Systemic lupus erythematosus (SLE) constitutes 10 to 20% of cases of SLE with more severe disease and higher mortality. We report a case of an adolescent girl with SLE with multisystem involvement who was started on hydroxychloroquine and oral prednisolone. However, due to persistent worsening of skin lesions and falling cell counts, pulsed dexamethasone was initiated which showed improvement in the skin lesions, cell counts, proteinuria and pleural effusion but there was a persistent fall in the haemoglobin.
View Article and Find Full Text PDFMycoses
January 2025
Department of Dermatology, Venereology and Leprosy, JSS Medical College and Hospital, JSS Academy of Higher Education and Research (JSSAHER) (Deemed to Be University), Mysuru, Karnataka, India.
Background: Tinea corporis (TC) is a common fungal infection affecting 20%-25% of the global population. Though diagnosing TC is straightforward, treatment has become challenging due to the use of certain medications and lack of follow-up, leading to resistance. Andrea et al.
View Article and Find Full Text PDFJpn J Ophthalmol
January 2025
Miyata Eye Hospital, 6-3, Kuraharacho, Miyakonojo, 885-0051, Miyazaki, Japan.
Purpose: This study aimed to report the incidence, characteristics, and prognosis of corneal perforation in patients with leprosy.
Study Design: Retrospective observational study.
Methods: Patients who presented with leprosy and visited a specialised ophthalmology hospital (Miyata Eye Hospital, Miyazaki, Japan) between 1980 and 2020 were included.
Front Immunol
January 2025
Programa Multicêntrico de Bioquímica e Biologia Molecular/PMBqBM - Universidade Federal de Juiz de Fora - UFJF, Governador Valadares, MG, Brazil.
Introduction: Leprosy, a chronic infectious disease, is closely linked to the host immune response. According to the WHO, leprosy patients (L) and household contacts (HHC) are classified into subgroups: paucibacillary (PB) and multibacillary (MB), witch reflect the degree of infection in patients and the level of exposure of their contacts. The main goal of this study was to: i) establish a comprehensive overview of soluble mediator signatures of PBMCs upon antigen-specific stimuli and ii) identify whether the chemokine (CH) and cytokine (CY) signatures were associated with distinct clinical manifestations in (L) and immune response profiles in (HHC).
View Article and Find Full Text PDFBMJ Open
December 2024
Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Central, Uganda.
Introduction: Tuberculosis (TB) is the leading infectious cause of death globally. Despite WHO recommendations for TB preventive therapy (TPT), challenges persist, including incompletion of treatment and adverse drug reactions (ADRs). There is limited data on the 3-month isoniazid and rifapentine (3HP) pharmacokinetics, pharmacogenomics and their relation with ADRs.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!